Incyte(INCY) - 2025 Q4 - Annual Results

Financial Performance - Total revenue for Q4 2025 was $1.51 billion, a 28% increase year-over-year, and $5.14 billion for the full year 2025, a 21% increase year-over-year[1][6][7] - Total net product revenue for Q4 2025 was $1.22 billion, a 20% increase year-over-year, exceeding the full year 2025 guidance of $4.23 - $4.32 billion[1][7][11] - Total GAAP revenues for the quarter ended December 31, 2025, were $1.51 billion, representing a 28% increase compared to $1.18 billion in the same period of 2024[31] - Total net product revenues for the quarter increased 20% to $1.22 billion, driven by significant growth in Jakafi and Opzelura sales[32] - Product revenues for Q4 2025 reached $1,222.8 million, a 19.9% increase from $1,019.4 million in Q4 2024[75] - Total revenues for the twelve months ended December 31, 2025, were $5,141.2 million, up 21.3% from $4,241.2 million in 2024[75] - Net income for Q4 2025 was $299.3 million, a significant increase from $201.2 million in Q4 2024, representing a 48.8% growth[75] - Non-GAAP net income for Q4 2025 was $368.0 million, compared to $281.4 million in Q4 2024, marking a 30.7% increase[78] - Basic net income per share for Q4 2025 was $1.52, up from $1.04 in Q4 2024, reflecting a 46.2% increase[75] Revenue Guidance - Full year 2026 total net product revenue guidance is set at $4.77 - $4.94 billion, including Jakafi revenue of $3.22 - $3.27 billion and Opzelura revenue of $750 - $790 million[1][8][9] - Incyte's financial guidance for 2026 includes expectations for sales of Jakafi and Opzelura, along with anticipated revenue contributions from other hematology and oncology products like Niktimvo and Zynyz[71] Expenses - GAAP R&D expenses for the full year 2025 were $2.1 billion, a decrease of 21% compared to the prior year, while SG&A expenses were $1.4 billion, an increase of 11%[11] - Research and development expenses for Q4 2025 increased 31% to $611 million, primarily due to investments in late-stage development assets[37] - Selling, general, and administrative expenses for Q4 2025 rose 19% to $390 million, driven by costs associated with US oncology product launches[38] Cash and Assets - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $3.6 billion, up from $2.2 billion as of December 31, 2024[11] - Cash, cash equivalents, and marketable securities increased to $3,580.6 million as of December 31, 2025, up from $2,158.1 million in 2024[77] - Total assets grew to $6,958.0 million in 2025, a 27.7% increase from $5,444.3 million in 2024[77] - Stockholders' equity increased to $5,167.5 million in 2025, compared to $3,447.6 million in 2024, indicating a 49.9% growth[77] Clinical Trials and Regulatory Submissions - Incyte expects to have fourteen pivotal clinical trials underway by the end of 2025, reflecting strong pipeline progress[4] - The Company plans to file a supplemental Biologics License Application for tafasitamab in first-line DLBCL in the first half of 2026[12] - A regulatory decision for Jakafi XR is expected in mid-2026 following a response to the FDA's complete response letter[13] - The MAA for povorcitinib in hidradenitis suppurativa was submitted to the EMA at the end of 2025, with potential approval anticipated by the end of 2026[27] - Regulatory submissions and approvals are expected for Jakafi XR, Opzelura in Europe, Zynyz, Monjuvi, and povorcitinib[71] Product Highlights - Jakafi net product revenue for Q4 2025 was $828 million, a 7% increase year-over-year, with a total of $3.09 billion for the year, up 11%[32] - Opzelura net product revenue for Q4 2025 reached $207 million, a 28% increase, with annual revenue of $678 million, up 33%[32] - Jakafi is approved for multiple indications, including polycythemia vera and myelofibrosis, with a focus on patients who have had inadequate responses to other treatments[50] - Opzelura is the first and only treatment for repigmentation approved for nonsegmental vitiligo in the U.S., highlighting its unique market position[51] - Monjuvi has received accelerated approval for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma, expanding its therapeutic reach[56] - Pemazyre is approved for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma, showcasing its targeted treatment capabilities[59] - Niktimvo is a first-in-class therapy for chronic GVHD, currently being studied in combination trials, indicating ongoing innovation in treatment options[68] Other Financial Metrics - The company recorded a contract dispute settlement of $242.2 million for the year, reflecting the difference between accrued royalties and total payments to Novartis[39] - An asset impairment charge of $76.3 million was recorded in Q4 2025 related to downtown Wilmington properties[40] - The company reported milestone revenues of $100.0 million for Q4 2025, compared to $0 in Q4 2024[78]